With each step made towards market for lecanemab, the sorry saga of its failed predecessor Aduhelm (aducanumab) seems further away for Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523).
The latest update on lecanemab led the drug companies behind both Alzheimer’s disease candidates to gain ground during Wednesday’s stock market trading, with Eisai closing nearly 4% higher and Biogen up by 5% by lunchtime.
"This is only a start to stopping Alzheimer’s"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze